BCR/ABL1 INHIBITOR RESISTANCE

Message

Need the patient's fusion type (p210, p190, p205, or p230).
*Collect specimen Monday through Thursday only before 1430 EST. Do not collect the day before a holiday.

Test Code

LAB00157

Alias/See Also

LAB00157
Mayo TC: BAKDM
Mayo Test Name: BCR/ABL1, Tyrosine Kinase Inhibitor Resistance, Kinase Domain Mutation Screen, Sanger Sequencing

CPT Codes
81406

Preferred Specimen

10 mL Lavender (EDTA) - Whole Blood

Minimum Volume

8 mL Lavender (EDTA) - Whole Blood

Other Acceptable Specimens

2-4 mL Bone Marrow submitted in an EDTA tube.

Instructions

If BCR/ABL1 fusion type (p190, p205, p210, or p230) is not provided, the qualitative, diagnostic assay for BCR/ABL1 will be performed at an additional charge. If no fusion form (p190, p205, p210, p230) is identified by qualitative testing, this test will be canceled.

Transport Temperature

Refrigerated

Specimen Stability

Refrigerated: 5 days

Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)

Gross hemolysis, moderately to severley clotted

Methodology
Reverse Transcription Polymerase Chain Reaction (RT-PCR) with Sanger Sequencing

Report Available

5-7 days

Clinical Significance

Evaluating patients with chronic myelogenous leukemia and Philadelphia chromosome positive B-cell acute lymphoblastic leukemia receiving tyrosine kinase inhibitor (TKI) therapy, who are apparently failing treatment.
Preferred initial test to identify the presence of acquired BCR/ABL1 mutations associated with TKI-resistance.

Performing Laboratory
Mayo Clinic Laboratories

The CPT Codes provided in this document are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payor being billed. Any Profile/panel component may be ordered separately. Reflex tests are performed at an additional charge.